serine has been researched along with Lewy Body Disease in 12 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
Lewy Body Disease: A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)
| Excerpt | Relevance | Reference |
|---|---|---|
| "α-Synuclein (α-syn) phosphorylation at serine 129 (pS129–α-syn) is substantially increased in Lewy body disease, such as Parkinson’s disease (PD) and dementia with Lewy bodies (DLB)." | 4.12 | α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. ( Abdi, IY; Ardah, MT; Attems, J; Carloni, P; Dorn, A; El-Agnaf, OMA; Erskine, D; Fayyad, M; Ghanem, SS; Jensen, NM; Jensen, PH; Majbour, NK; McKeith, I; Melachroinou, K; Outeiro, TF; Poggiolini, I; Santos, P; Sudhakaran, IP; Vaikath, NN; Vasili, E; Vekrellis, K, 2022) |
| "Increasing evidence suggests that phosphorylation may play an important role in the oligomerization, fibrillogenesis, Lewy body (LB) formation, and neurotoxicity of alpha-synuclein (alpha-syn) in Parkinson disease." | 3.76 | Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. ( Aebischer, P; Chegini, F; Chiappe, D; Eliezer, D; Fernandez, CO; Gai, WP; Kim, HY; Lamberto, GR; Lashuel, HA; Masliah, E; Moniatte, M; Oueslati, A; Paleologou, KE; Rospigliosi, CC; Schmid, A; Schneider, BL; Shakked, G; Zweckstetter, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sano, K | 1 |
| Iwasaki, Y | 1 |
| Yamashita, Y | 1 |
| Irie, K | 1 |
| Hosokawa, M | 1 |
| Satoh, K | 1 |
| Mishima, K | 1 |
| Ghanem, SS | 2 |
| Majbour, NK | 2 |
| Vaikath, NN | 2 |
| Ardah, MT | 1 |
| Erskine, D | 2 |
| Jensen, NM | 1 |
| Fayyad, M | 2 |
| Sudhakaran, IP | 2 |
| Vasili, E | 1 |
| Melachroinou, K | 1 |
| Abdi, IY | 1 |
| Poggiolini, I | 1 |
| Santos, P | 1 |
| Dorn, A | 1 |
| Carloni, P | 1 |
| Vekrellis, K | 2 |
| Attems, J | 2 |
| McKeith, I | 1 |
| Outeiro, TF | 1 |
| Jensen, PH | 1 |
| El-Agnaf, OMA | 2 |
| Abdesselem, H | 1 |
| Lamprokostopoulou, A | 1 |
| Morris, CM | 1 |
| Miners, JS | 1 |
| Renfrew, R | 1 |
| Swirski, M | 1 |
| Love, S | 1 |
| Schell, H | 1 |
| Hasegawa, T | 1 |
| Neumann, M | 1 |
| Kahle, PJ | 1 |
| Paleologou, KE | 1 |
| Oueslati, A | 1 |
| Shakked, G | 1 |
| Rospigliosi, CC | 1 |
| Kim, HY | 1 |
| Lamberto, GR | 1 |
| Fernandez, CO | 1 |
| Schmid, A | 1 |
| Chegini, F | 1 |
| Gai, WP | 2 |
| Chiappe, D | 1 |
| Moniatte, M | 1 |
| Schneider, BL | 1 |
| Aebischer, P | 1 |
| Eliezer, D | 1 |
| Zweckstetter, M | 1 |
| Masliah, E | 1 |
| Lashuel, HA | 1 |
| Lim, Y | 1 |
| Kehm, VM | 1 |
| Lee, EB | 1 |
| Soper, JH | 1 |
| Li, C | 1 |
| Trojanowski, JQ | 1 |
| Lee, VM | 1 |
| Muntané, G | 1 |
| Ferrer, I | 1 |
| Martinez-Vicente, M | 1 |
| Walker, DG | 1 |
| Lue, LF | 1 |
| Adler, CH | 1 |
| Shill, HA | 1 |
| Caviness, JN | 1 |
| Sabbagh, MN | 1 |
| Akiyama, H | 2 |
| Serrano, GE | 1 |
| Sue, LI | 1 |
| Beach, TG | 1 |
| Anderson, JP | 1 |
| Walker, DE | 1 |
| Goldstein, JM | 1 |
| de Laat, R | 1 |
| Banducci, K | 1 |
| Caccavello, RJ | 1 |
| Barbour, R | 1 |
| Huang, J | 1 |
| Kling, K | 1 |
| Lee, M | 1 |
| Diep, L | 1 |
| Keim, PS | 1 |
| Shen, X | 1 |
| Chataway, T | 1 |
| Schlossmacher, MG | 1 |
| Seubert, P | 1 |
| Schenk, D | 1 |
| Sinha, S | 1 |
| Chilcote, TJ | 1 |
| Obi, K | 1 |
| Kondo, H | 1 |
| Shimomura, Y | 1 |
| Hasegawa, M | 1 |
| Iwatsubo, T | 1 |
| Mizuno, Y | 1 |
| Mochizuki, H | 1 |
| Mata, IF | 1 |
| Samii, A | 1 |
| Schneer, SH | 1 |
| Roberts, JW | 1 |
| Griffith, A | 1 |
| Leis, BC | 1 |
| Schellenberg, GD | 1 |
| Sidransky, E | 1 |
| Bird, TD | 1 |
| Leverenz, JB | 1 |
| Tsuang, D | 1 |
| Zabetian, CP | 1 |
12 other studies available for serine and Lewy Body Disease
| Article | Year |
|---|---|
Tyrosine 136 phosphorylation of α-synuclein aggregates in the Lewy body dementia brain: involvement of serine 129 phosphorylation by casein kinase 2.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Amino Acid Substitution; Autopsy; Brain; Casein Kinase II; | 2021 |
α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.
Topics: alpha-Synuclein; Amyloid; Humans; Lewy Body Disease; Parkinson Disease; Phosphorylation; Protein Agg | 2022 |
Investigating the presence of doubly phosphorylated α-synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Animals; Female; Humans; Lewy Body Disease; Male; Mice; Ph | 2020 |
Accumulation of α-synuclein in dementia with Lewy bodies is associated with decline in the α-synuclein-degrading enzymes kallikrein-6 and calpain-1.
Topics: alpha-Synuclein; Alzheimer Disease; Brain; Calpain; Case-Control Studies; Cell Line, Tumor; Child; C | 2014 |
Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
Topics: Aging; alpha-Synuclein; Amygdala; Animals; Brain; Cell Nucleus; Cells, Cultured; Cerebral Cortex; Co | 2009 |
Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
Topics: alpha-Synuclein; Alzheimer Disease; Amino Acid Sequence; Animals; Brain; Cell Membrane; Creatine Kin | 2010 |
α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.
Topics: Acoustic Stimulation; Age Factors; alpha-Synuclein; Analysis of Variance; Animals; Animals, Newborn; | 2011 |
α-synuclein phosphorylation and truncation are normal events in the adult human brain.
Topics: Adult; Aged; Aged, 80 and over; alpha-Synuclein; Animals; Brain; Cell Line, Tumor; Female; Humans; L | 2012 |
Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Female; Gyrus Cinguli; Humans; Lewy Body Disease; Male; Pa | 2013 |
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.
Topics: alpha-Synuclein; Amino Acid Sequence; Female; Humans; Lewy Body Disease; Middle Aged; Molecular Sequ | 2006 |
Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Amyloid beta-Peptides; Analysis of Variance; Cerebral Cort | 2008 |
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders.
Topics: Aged; Asparagine; Case-Control Studies; DNA Mutational Analysis; Female; Gene Frequency; Genetic Pre | 2008 |